Who Paid My Doc
Hemoblast Bellows
Device Hemostatic Agent
PDI 03760193182705
General payments
$1,291,847
Research payments
$537,574
Through program year 2025, $1,291,847 in general payments and $537,574 in research payments were reported against Hemoblast Bellows (Hemostatic Agent).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
9 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $669,805 | 2,681 |
| 2025 | Research | $3,419 | 1 |
| 2024 | General | $148,514 | 1,797 |
| 2024 | Research | $118,500 | 7 |
| 2023 | General | $191,538 | 1,296 |
| 2023 | Research | $27,348 | 2 |
| 2022 | General | $7,828 | 59 |
| 2021 | General | $274,163 | 1,166 |
| 2021 | Research | $388,308 | 13 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 74 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 45 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
6,999 general · 23 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.